secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phathom Pharmaceuticals, Inc. (PHAT)
CIK:        0001783183
Form:       8-K
Filed at:   2024-03-07T23:59:59+00:00
Accession:  0001193125-24-061512
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phathom reports Q4/FY2023 results; VOQUEZNA launch nets $0.7M revenue, cash runway extended to 2026
--------------------------------------------------------------------------------

- Q4 net revenue $0.7M from VOQUEZNA launch; cumulative prescriptions over 14,000 as of Feb 23, 2024.
- Expanded term loan facility up to $300M with more favorable terms; access to $160M additional; cash runway through 2026.
- Express Scripts added VOQUEZNA to formularies; ~60M commercial lives covered (~38% of U.S. commercial).
- FDA accepted NDA for Non-Erosive GERD; PDUFA July 19, 2024; launch expected upon approval.
- Net loss Q4 $79.6M ($46M non-GAAP adjusted); G&A up due to commercial build and stock-based comp.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783183/000119312524061512/0001193125-24-061512-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783183/000119312524061512/d759734d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-061512

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer